Dianthus Gross Profit vs Operating Income Analysis

DNTH Stock

22.96 1.77 7.16%

Dianthus Therapeutics financial indicator trend analysis is much more than just examining Dianthus Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Dianthus Therapeutics is a good investment. Please check the relationship between Dianthus Therapeutics Gross Profit and its Operating Income accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.

Gross Profit vs Operating Income

Gross Profit vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Dianthus Therapeutics Gross Profit account and Operating Income. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Dianthus Therapeutics' Gross Profit and Operating Income is 0.12. Overlapping area represents the amount of variation of Gross Profit that can explain the historical movement of Operating Income in the same time period over historical financial statements of Dianthus Therapeutics, assuming nothing else is changed. The correlation between historical values of Dianthus Therapeutics' Gross Profit and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Gross Profit of Dianthus Therapeutics are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Gross Profit i.e., Dianthus Therapeutics' Gross Profit and Operating Income go up and down completely randomly.

Correlation Coefficient

0.12

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Dianthus Therapeutics minus its cost of goods sold. It is profit before Dianthus Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Operating Income

Operating Income is the amount of profit realized from Dianthus Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Dianthus Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Dianthus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Dianthus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.As of now, Dianthus Therapeutics' Sales General And Administrative To Revenue is increasing as compared to previous years. The Dianthus Therapeutics' current Enterprise Value Over EBITDA is estimated to increase to 1.53, while Selling General Administrative is projected to decrease to under 14.9 M.

	2024	2025 (projected)
Interest Expense	4.1M	2.7M
Depreciation And Amortization	408.3K	387.8K

Interest Expense Depreciation And Amortization

Dianthus Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Non Currrent Assets Other	Other Assets	Short Term Investments	Non Current Liabilities Total	Net Tangible Assets	Inventory	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.89	0.94	0.87	0.54	-0.88	-0.78	0.75	0.82	0.65	1.0	-0.8	0.53	0.97	0.59	0.16	1.0	0.41	0.63	0.63	-0.44	0.01	-0.54	0.59	0.58	0.57
Other Current Liab	0.89		0.98	0.71	0.68	-0.72	-0.82	0.58	0.68	0.71	0.88	-0.81	0.39	0.92	0.65	0.37	0.88	0.67	0.53	0.58	-0.41	0.22	-0.45	0.45	0.37	0.46
Total Current Liabilities	0.94	0.98		0.78	0.69	-0.75	-0.85	0.71	0.71	0.75	0.93	-0.8	0.41	0.95	0.68	0.3	0.93	0.64	0.56	0.58	-0.4	0.15	-0.45	0.46	0.42	0.46
Total Stockholder Equity	0.87	0.71	0.78		0.43	-0.93	-0.69	0.74	0.92	0.55	0.87	-0.82	0.39	0.88	0.61	-0.24	0.87	0.1	0.67	0.55	-0.37	-0.38	-0.43	0.42	0.75	0.41
Property Plant And Equipment Net	0.54	0.68	0.69	0.43		-0.24	-0.88	0.56	0.16	0.87	0.51	-0.39	-0.17	0.63	0.47	0.05	0.51	0.45	0.41	-0.08	0.3	-0.05	0.22	-0.21	-0.18	-0.21
Net Debt	-0.88	-0.72	-0.75	-0.93	-0.24		0.56	-0.54	-0.98	-0.33	-0.89	0.85	-0.64	-0.86	-0.54	0.05	-0.88	-0.14	-0.66	-0.75	0.62	0.18	0.67	-0.66	-0.86	-0.66
Retained Earnings	-0.78	-0.82	-0.85	-0.69	-0.88	0.56		-0.75	-0.49	-0.83	-0.77	0.65	-0.14	-0.8	-0.64	-0.1	-0.77	-0.53	-0.44	-0.27	0.0	0.03	0.12	-0.11	-0.17	-0.11
Accounts Payable	0.75	0.58	0.71	0.74	0.56	-0.54	-0.75		0.51	0.72	0.73	-0.48	0.18	0.73	0.62	-0.13	0.73	0.29	0.42	0.26	-0.1	-0.25	-0.14	0.18	0.35	0.16
Cash	0.82	0.68	0.71	0.92	0.16	-0.98	-0.49	0.51		0.25	0.83	-0.82	0.64	0.8	0.51	-0.05	0.83	0.1	0.65	0.8	-0.65	-0.17	-0.71	0.68	0.91	0.69
Non Current Assets Total	0.65	0.71	0.75	0.55	0.87	-0.33	-0.83	0.72	0.25		0.62	-0.49	-0.25	0.7	0.51	0.02	0.62	0.46	0.35	-0.07	0.25	-0.1	0.18	-0.17	-0.12	-0.18
Cash And Short Term Investments	1.0	0.88	0.93	0.87	0.51	-0.89	-0.77	0.73	0.83	0.62		-0.81	0.56	0.97	0.59	0.16	1.0	0.41	0.63	0.65	-0.47	0.01	-0.56	0.61	0.6	0.59
Net Receivables	-0.8	-0.81	-0.8	-0.82	-0.39	0.85	0.65	-0.48	-0.82	-0.49	-0.81		-0.47	-0.82	-0.8	0.01	-0.8	-0.44	-0.32	-0.55	0.56	0.15	0.4	-0.4	-0.6	-0.39
Common Stock Shares Outstanding	0.53	0.39	0.41	0.39	-0.17	-0.64	-0.14	0.18	0.64	-0.25	0.56	-0.47		0.47	0.34	0.27	0.56	0.22	0.28	0.83	-0.88	0.21	-0.79	0.89	0.73	0.85
Other Current Assets	0.97	0.92	0.95	0.88	0.63	-0.86	-0.8	0.73	0.8	0.7	0.97	-0.82	0.47		0.65	0.08	0.97	0.39	0.69	0.56	-0.41	-0.07	-0.44	0.49	0.54	0.47
Other Stockholder Equity	0.59	0.65	0.68	0.61	0.47	-0.54	-0.64	0.62	0.51	0.51	0.59	-0.8	0.34	0.65		-0.13	0.58	0.56	0.03	0.29	-0.45	-0.25	-0.08	0.1	0.36	0.08
Total Liab	0.16	0.37	0.3	-0.24	0.05	0.05	-0.1	-0.13	-0.05	0.02	0.16	0.01	0.27	0.08	-0.13		0.16	0.7	-0.06	0.46	-0.3	0.99	-0.51	0.48	-0.15	0.52
Total Current Assets	1.0	0.88	0.93	0.87	0.51	-0.88	-0.77	0.73	0.83	0.62	1.0	-0.8	0.56	0.97	0.58	0.16		0.4	0.64	0.65	-0.47	0.02	-0.57	0.62	0.6	0.6
Common Stock	0.41	0.67	0.64	0.1	0.45	-0.14	-0.53	0.29	0.1	0.46	0.41	-0.44	0.22	0.39	0.56	0.7	0.4		-0.18	0.34	-0.33	0.62	-0.23	0.22	-0.12	0.24
Non Currrent Assets Other	0.63	0.53	0.56	0.67	0.41	-0.66	-0.44	0.42	0.65	0.35	0.63	-0.32	0.28	0.69	0.03	-0.06	0.64	-0.18		0.46	-0.13	-0.15	-0.45	0.43	0.53	0.43
Other Assets	0.63	0.58	0.58	0.55	-0.08	-0.75	-0.27	0.26	0.8	-0.07	0.65	-0.55	0.83	0.56	0.29	0.46	0.65	0.34	0.46		-0.84	0.37	-0.96	0.93	0.8	0.95
Short Term Investments	-0.44	-0.41	-0.4	-0.37	0.3	0.62	0.0	-0.1	-0.65	0.25	-0.47	0.56	-0.88	-0.41	-0.45	-0.3	-0.47	-0.33	-0.13	-0.84		-0.24	0.79	-0.81	-0.74	-0.81
Non Current Liabilities Total	0.01	0.22	0.15	-0.38	-0.05	0.18	0.03	-0.25	-0.17	-0.1	0.01	0.15	0.21	-0.07	-0.25	0.99	0.02	0.62	-0.15	0.37	-0.24		-0.45	0.42	-0.24	0.46
Net Tangible Assets	-0.54	-0.45	-0.45	-0.43	0.22	0.67	0.12	-0.14	-0.71	0.18	-0.56	0.4	-0.79	-0.44	-0.08	-0.51	-0.57	-0.23	-0.45	-0.96	0.79	-0.45		-0.96	-0.75	-0.98
Inventory	0.59	0.45	0.46	0.42	-0.21	-0.66	-0.11	0.18	0.68	-0.17	0.61	-0.4	0.89	0.49	0.1	0.48	0.62	0.22	0.43	0.93	-0.81	0.42	-0.96		0.73	0.99
Net Invested Capital	0.58	0.37	0.42	0.75	-0.18	-0.86	-0.17	0.35	0.91	-0.12	0.6	-0.6	0.73	0.54	0.36	-0.15	0.6	-0.12	0.53	0.8	-0.74	-0.24	-0.75	0.73		0.73
Property Plant And Equipment Gross	0.57	0.46	0.46	0.41	-0.21	-0.66	-0.11	0.16	0.69	-0.18	0.59	-0.39	0.85	0.47	0.08	0.52	0.6	0.24	0.43	0.95	-0.81	0.46	-0.98	0.99	0.73

Click cells to compare fundamentals

Dianthus Therapeutics Account Relationship Matchups

Dianthus Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	161.6M	9.5M	83.1M	179.4M	206.3M	112.5M
Other Current Liab	7.7M	4.0M	6.6M	6.5M	7.5M	6.5M
Total Current Liabilities	11.4M	5.4M	8.2M	9.6M	11.1M	9.0M
Total Stockholder Equity	143.9M	(17.2M)	(44.4M)	168.9M	194.2M	203.9M
Property Plant And Equipment Net	8.3M	33K	956K	800K	720K	684K
Net Debt	(58.2M)	(7.6M)	(14.6M)	(131.7M)	(118.6M)	(112.6M)
Retained Earnings	(254.4M)	(17.4M)	(45.9M)	(89.4M)	(80.5M)	(84.5M)
Accounts Payable	3.8M	1.4M	1.2M	2.6M	3.0M	2.3M
Cash	58.2M	7.6M	15.4M	132.3M	152.2M	159.8M
Non Current Assets Total	10.1M	63K	1.1M	2.0M	1.8M	1.7M
Cash And Short Term Investments	148.8M	7.6M	75.5M	173.7M	199.8M	103.1M
Common Stock Shares Outstanding	2.7M	3.4M	3.7M	5.2M	5.9M	3.2M
Liabilities And Stockholders Equity	161.6M	9.5M	83.1M	179.4M	206.3M	112.5M
Other Current Assets	2.7M	274K	905K	3.3M	3.7M	2.1M
Other Stockholder Equity	398.3M	498.3M	(116.4M)	258.2M	297.0M	221.6M
Total Liab	17.7M	26.7M	127.5M	10.5M	12.1M	11.5M
Total Current Assets	151.5M	9.4M	82.0M	177.5M	204.1M	107.1M
Accumulated Other Comprehensive Income	(23K)	(30K)	(161K)	47K	54.1K	56.8K
Common Stock	49K	59K	61K	15K	17.3K	16.4K
Non Currrent Assets Other	1.0	(1.8M)	61K	1.1M	979.2K	1.0M
Short Term Investments	90.7M	45.3M	60.1M	41.4M	37.3M	53.6M
Non Current Liabilities Total	6.3M	21.3M	119.3M	904K	1.0M	987.6K

Currently Active Assets on Macroaxis

V	Visa Class A
GM	General Motors
C	Citigroup
BAC	Bank of America
DD	Dupont De Nemours

When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:

How To Invest In Dianthus

Details

Is Dianthus Stock a good investment?

Details

What is Dianthus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.

You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

7.22

Revenue Per Share

0.19

Quarterly Revenue Growth

1.351

Return On Assets

(0.19)

Return On Equity

(0.26)

The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Dianthus Gross Profit vs Operating Income Analysis

Gross Profit vs Operating Income

Gross Profit vs Operating Income Correlation Analysis

Correlation Coefficient

Gross Profit

Operating Income

Dianthus Therapeutics fundamental ratios Correlations

Dianthus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Dianthus Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Non Current Liabilities Total	+ 0.99	Total Liab
Property Plant And Equipment Gross	+ 0.99	Inventory
Total Current Liabilities	+ 0.98	Other Current Liab

Property Plant And Equipment Gross	- 0.98	Net Tangible Assets
Cash	- 0.98	Net Debt
Inventory	- 0.96	Net Tangible Assets
Net Tangible Assets	- 0.96	Other Assets
Net Debt	- 0.93	Total Stockholder Equity
Cash And Short Term Investments	- 0.89	Net Debt